Aggressive Breast Cancer Responds to New Drug

In the clinical trial of the new drug, sacituzumab govitecan, about a third of the patients responded to treatment and the effect lasted up to eight months. The research was funded by the drug's maker.
Source: WebMD Health - Category: Consumer Health News Source Type: news